CLASSIC IMMUNOTOXINS WITH PLANT OR MICROBIAL TOXINS - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 282

134. Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P,
Fitzgerald DJ, Wilson WH, et al. (2009) Phase II trial of
recombinant

lesions in patients intratumorally injected with a recombinant
single-chain antibody-toxin targeted to ErbB2/HER2. Breast
Cancer Res. Treat. 82, 155-164.
148. van Oosterhout YV, van Emst L, Schattenberg AV, Tax WJ,
Ruiter DJ, Spits H, et al. (2000) A combination of anti-CD3
and anti-CD7 ricin A-immunotoxins for the in vivo treatment
of acute graft versus host disease. Blood 95, 3693-3701.
149. Grossbard ML, Freedman AS, Ritz J, Coral F, Goldmacher
VS, Eliseo L, et al. (1992) Serotherapy of B-cell neoplasms
with anti-B4-blocked ricin: a Phase I trial of daily bolus
infusion. Blood 79, 576-585.
150. Stone MJ, Sausville EA, Fay JW, Headlee D, Collins RH,
Figg WD, et al. (1996) A Phase I study of bolus versus
continuous infusion of the anti-CD19 immunotoxin, IgG-
HD37-dgA, in patients with B-cell lymphoma. Blood 88,
1188-1197.
151. Seibel NL, Krailo M, O'Neill K, Franklin J, Uckun F, Reaman
GH. (1999) Phase I study of B43-PAP immunotoxin in
combination with standard 4-drug induction for patients
with CD19 þ acute lymphoblastic leukemia (ALL) in relapse,
a children's cancer group study. Pediatr. Res. 45, 775.
152. Herrera L, Bostrom B, Gore L, Sandler E, Lew G, Schlegel
PG, et al. (2009) A Phase 1 study of Combotox in pediatric
patients with refractory B-lineage acute lymphoblastic leu-
kemia. J Pediatr Hematol Oncol 31, 936-941.
153. Sausville EA, Headlee D, Stetler-Stevenson M, Jaffe ES,
Solomon D, Figg WD, et al. (1995) Continuous infusion
of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in
patients with B-cell lymphoma: a Phase I study. Blood 85,
3457-3465.
154. Amlot PL, Stone MJ, Cunningham D, Fay J, Newman J,
Collins R, et al. (1993) A Phase I study of an anti-CD22-
deglycosylated ricin A chain immunotoxin in the treatment of
B-cell lymphomas resistant to conventional therapy. Blood
82, 2624-2633.
155. Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B,
Hansen H, et al. (2002) A Phase I study with an anti-CD30
ricin A-chain immunotoxin (Ki-4.dgA) in patients with
refractory CD30 þ Hodgkin's and non-Hodgkin's lymphoma.
Clin. Cancer Res. 8, 1779-1786.
156. Fidias P, Grossbard M, Lynch TJ. Jr. (2002) A Phase II study
of the immunotoxin N901-blocked ricin in small-cell lung
cancer. Clin. Lung Cancer 3, 219-222.
157. Hellstrom I, Garrigues HJ, Garrigues U, Hellstrom KE.
(1990) Highly tumor-reactive, internalizing, mouse monoclo-
nal antibodies to Le(y)-related cell surface antigens. Cancer
Res. 50, 2183-2190.
158. Gould BJ, Borowitz MJ, Groves ES, Carter PW, Anthony D,
Weiner LM, et al. (1989) Phase I study of an anti-breast
cancer immunotoxin by continuous infusion: report of a
targeted toxic effect not predicted by animal studies.
J. Natl. Cancer Inst. 81, 775-781.
159. Pai LH, Bookman MA, Ozols RF, Young RC, Smith JW, 2nd,
Longo DL, et al. (1991) Clinical evaluation of intraperitoneal
Pseudomonas exotoxin immunoconjugate OVB3-PE in
patients with ovarian cancer. J. Clin. Oncol. 9, 2095-2103.

immunotoxin RFB4(dsFv)-PE38 (BL22) in

patients with hairy cell leukemia. J. Clin. Oncol. 27,

2983-2990.
135. Salvatore G, Beers R, Margulies I, Kreitman RJ, Pastan I.
(2002) Improved cytotoxic activity toward cell lines and fresh
leukemia cells of a mutant anti-CD22 immunotoxin obtained
by antibody phage display. Clin. Cancer Res. 8, 995-1002.
136. Kreitman RJ, Tallman MS, Coutre SE, Robak T, Wilson WH,
Stetler-Stevenson M, et al. (2010) Phase I trial of recombinant
immunotoxin CAT-8015 (HA22) in multiply relapsed hairy
cell leukemia. J. Clin. Oncol. 28, 6523.
137. Powell DJ. Jr., Felipe-Silva A, Merino MJ, Ahmadzadeh M,
Allen T, Levy C, et al. (2007) Administration of a CD25-
directed immunotoxin, LMB-2, to patients with metastatic
melanoma induces a selective partial reduction in regulatory
T cells in vivo. J. Immunol. 179, 4919-4928.
138. Frankel AE, Zuckero SL, Mankin AA, Grable M, Mitchell K,
Lee YJ, et al. (2009) Anti-CD3 recombinant diphtheria
immunotoxin therapy of cutaneous T cell lymphoma. Curr.
Drug Targets 10, 104-109.
139. Laske DW, Youle RJ, Oldfield EH. (1997) Tumor regression
with regional distribution of the targeted toxin TF-CRM107
in patients with malignant brain tumors. Nat. Med. 3, 1362-
1368.
140. Noonan M. (2007) Celtic Pharma terminates Transmid trial
KSB311R/CIII/001 (Feb 7. 2007). Drugscom.
141. Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF,
Piepmeier JM, et al. (2007) Direct intracerebral delivery of
cintredekin besudotox (IL13-PE38QQR) in recurrent malig-
nant glioma: a report by the Cintredekin Besudotox Intra-
parenchymal Study Group. J. Clin. Oncol. 25, 837-844.
142. Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J,
Barnett G, et al. (2010) Phase III randomized trial of CED of
IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.
Neuro. Oncol. 12, 871-881.
143. Byers VS, Henslee PJ, Kernan NA, Blazar BR, Gingrich R,
Phillips GL, et al. (1990) Use of an anti-pan T-lymphocyte
ricin a chain immunotoxin in steroid-resistant acute graft-
versus-host disease. Blood 75, 1426-1432.
144. Martin PJ, Nelson BJ, Appelbaum FR, Anasetti C, Deeg HJ,
Hansen JA, et al. (1996) Evaluation of a CD5-specific immu-
notoxin for treatment of acute graft-versus-host disease after
allogeneic marrow transplantation. Blood 88, 824-830.
145. Byers VS, Rodvien R, Grant K, Durrant LG, Hudson KH,
Baldwin RW, et al. (1989) Phase I study of monoclonal
antibody-ricin A chain immunotoxin XomaZyme-791 in
patients with metastatic colon cancer. Cancer Res. 49,
6153-6160.
146. Goldberg MR, Heimbrook DC, Russo P, Sarosdy MF, Green-
berg RE, Giantonio BJ, et al. (1995) Phase I clinical study of
the recombinant oncotoxin TP40 in superficial bladder can-
cer. Clin. Cancer Res. 1, 57-61.
147. Azemar M, Djahansouzi S, Jager E, Solbach C, Schmidt M,
Maurer AB, et al. (2003) Regression of cutaneous tumor